Arch Biopartners Inc

Research Arch Biopartners Inc (ARCH) on Bullrun: market cap CAD 57.06M. Explore financials, valuation history, model signals, and stock context.

Key Metrics

• TickerARCH
• ExchangeV
• CountryCanada
• SectorHealthcare
• IndustryBiotechnology
• CurrencyCAD
• Market capCAD 57.06M
• Financial periodQ4 2025
• Net income-CAD 1.56M
• Free cash flow-CAD 849.94K

Valuation Snapshot

latest market cap is CAD 57.06M.

About Arch Biopartners Inc

Arch Biopartners Inc., together with its subsidiaries, engages in the development of novel drugs for acute kidney injury and organ damage in Canada. It focuses on developing its lead drug candidate LSALT Peptide, which is in Phase 2 trials to treat inflammation related acute kidney injury experienced by patients undergoing on-pump (bypass) cardiac surgery; and cilastatin to prevent toxin related acute kidney injury via dipeptidase-1.

Frequently asked questions

What is Arch Biopartners Inc's market cap?

Arch Biopartners Inc's market capitalization is CAD 57.06M.

What does Arch Biopartners Inc do?

Arch Biopartners Inc., together with its subsidiaries, engages in the development of novel drugs for acute kidney injury and organ damage in Canada.